Stockreport

CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Rating Downgrade) [Seeking Alpha]

CG Oncology, Inc. - Common stock  (CGON) 
PDF Cretostimogene grenadenorepvec remains the lead asset, targeting non-metastatic bladder cancer with pivotal data and a BLA submission expected in 2025-2026. A key upc [Read more]